Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224406 · ClinicalTrials.gov registry record · Phase 2
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
A Phase 2 study, sponsored by Dompé Farmaceutici S.p.A.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT00224406 is a Phase 2 study that has completed, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 114 participants.
The verdict
NCT00224406, a Phase 2 study, has completed, sponsored by Dompé Farmaceutici S.p.A.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
The objective of this clinical study was to evaluate whether CXCL8 (CXC ligand 8 \[formerly interleukin (IL)-8\]) inhibition with repertaxin leads to reduced severity of primary graft dysfunction, as the result of improved functional and clinical outcomes in lung transplantation patients. The safety of repertaxin in the specific clinical setting was also evaluated. The ability of repertaxin to reduce target cells (polymorphonuclear leukocyte \[PMN\]) infiltration into the graft was evaluated to confirm its mechanism of action.
Interventions
- OTHER Placebo
- DRUG Repertaxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2005-05-01 |
| Est. Completion | 2007-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224406
The ClinicalTrials.gov registry entry for NCT00224406 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00224406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224406 about?
NCT00224406 is a clinical study titled "Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation". The objective of this clinical study was to evaluate whether CXCL8 (CXC ligand 8 \[formerly interleukin (IL)-8\]) inhibition with repertaxin leads to reduced severity of primary graft dysfunction, as the result of improved functional and clinical outcomes in lung transplantation patients. The safet...
What is the current status of trial NCT00224406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2005-05-01. Estimated completion is 2007-09-13.
What interventions are being tested in trial NCT00224406?
The interventions under investigation include: Placebo (OTHER), Repertaxin (DRUG).
Who is sponsoring clinical trial NCT00224406?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.